The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pharmacogenomic determinants of cetuximab and oxaliplatin pharmacokinetics during combined intravenous cetuximab (IV-Cet) and triplet hepatic artery chronomodulated infusion in patients (pts) with initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU OPTILIV trial).
 
Abdoulaye Karaboue
No Relationships to Disclose
 
Raphael Saffroy
No Relationships to Disclose
 
Christophe Desterke
No Relationships to Disclose
 
Mohamed Bouchahda
No Relationships to Disclose
 
Pasquale Innominato
No Relationships to Disclose
 
C. N. J. Focan
No Relationships to Disclose
 
Etienne Chatelut
No Relationships to Disclose
 
Gilles Paintaud
No Relationships to Disclose
 
Gerard A. Milano
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - Merck; Onxeo; Pierre Fabre
 
Antoinette Lemoine
No Relationships to Disclose
 
Francis Levi
No Relationships to Disclose